National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings, 24321 [2018-11215]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 102 / Friday, May 25, 2018 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
amozie on DSK3GDR082PROD with NOTICES1
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Next Generation
Multipurpose Prevention Technologies
(NGM) (R61/R33 Clinical Trial Optional).
Date: June 12, 2018.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Audrey O. Lau, Ph.D.,
MPH, Scientific Review Officer AIDS
REVIEW BRANCH SRP, RM 3E70, National
Institutes of Health, NIAID, 5601 Fishers
Lane, MSC 9834, Rockville, MD 20852–9834,
240–669–2081, audrey.lau@nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Partnerships for
Countermeasures against Select Pathogens
(R01).
Date: June 28–29, 2018.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Amir E. Zeituni, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities
NIAID/NIH/DHHS, 5601 Fishers Lane, MSC–
9834, Rockville, MD 20852, 301–496–2550,
amir.zeituni@nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Partnerships for
Countermeasures against Select Pathogens
(R01).
Date: July 10–11, 2018.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
VerDate Sep<11>2014
18:28 May 24, 2018
Jkt 241001
Contact Person: Amir E. Zeituni, Ph.D.,
Scientific Review Officer Scientific Review
Program Division of Extramural Activities
NIAID/NIH/DHHS, 5601 Fishers Lane, MSC–
9834, Rockville, MD 20852, 301–496–2550,
amir.zeituni@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: May 21, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–11215 Filed 5–24–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
SUMMARY: The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing.
FOR FURTHER INFORMATION CONTACT: Dr.
Amy Petrik, 240–627–3721;
amy.petrik@nih.gov. Licensing
information and copies of the U.S.
patent application listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD, 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Antibodies and Methods for the
Diagnosis and Treatment of EpsteinBarr Virus Infection
Description of Technology
According to the World Health
Organization, over 90% of the
worldwide population is infected with
Epstein-Barr virus by adulthood. In
most cases, the disease accompanying
initial infection is subclinical though
some individuals who are infected as
adolescents or adults do experience
infectious mononucleosis. However,
once infected, individuals carry latent
EBV for their remaining lifespan. In
such individuals, immune suppression
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
24321
can result in reactivation of the EBV and
consequently, EBV-associated
lymphoproliferative disease. Currently,
there is no prophylactic to prevent
primary EBV infection and additional
therapeutics would be useful to treat
EBV-associated B-cell driven
lymphoproliferative disease.
Scientists at the NIAID are developing
neutralizing antibodies, originally
isolated from humans or non-human
primates, that could be useful in
preventing primary infection or
reactivation of EBV in
immunocompromised individuals.
These antibodies are 10–100 times more
potent than the most potent EBV
neutralizing antibody identified to date
(72A1). The antibodies target epitopes
on either the gp350 surface glycoprotein
of EBV or the gH/gL heterodimer. In
vitro experiments have demonstrated
that the antibodies effectively inhibit
EBV infection of B cells and epithelial
cells as well as cell-to-cell fusion of
cells expressing the viral proteins gH/
gL.
Potential Commercial Applications
• Treatment of individuals with
compromised immune systems to
prevent EBV-associated
lymphoproliferative diseases.
• Prevention of primary EBV
infection in individuals with
compromised immune systems to
prevent EBV-associated
lymphoproliferative diseases.
Competitive Advantages
• No EBV therapeutics or
prophylactics currently exist.
Development Stage
• In vitro
Inventors: Masaru Kanekiyo (NIAID),
W. Gordon Joyce (WRAIR), Wei Bu
(NIAID), Jeffrey Cohen (NIAID).
Publications: N/A.
Intellectual Property: HHS Reference
Number E–001–2017 includes U.S.
Provisional Patent Application No. 62/
490,023 filed April 25, 2017 (Pending);
PCT Application No. PCT/US2018/
29463 filed April 25, 2018.
HHS Reference Number E–079–2018
includes U.S. Provisional Patent
Application No. 62/665,977 filed May 2,
2018.
Related Intellectual Property: HHS
Reference Number E–001–2017; E–079–
2018.
Licensing Contact: Dr. Amy Petrik,
240–627–3721; amy.petrik@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
E:\FR\FM\25MYN1.SGM
25MYN1
]]>Agencies
[Federal Register Volume 83, Number 102 (Friday, May 25, 2018)]
[Notices]
[Page 24321]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-11215]
[[Page 24321]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Next Generation Multipurpose
Prevention Technologies (NGM) (R61/R33 Clinical Trial Optional).
Date: June 12, 2018.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Audrey O. Lau, Ph.D., MPH, Scientific Review
Officer AIDS REVIEW BRANCH SRP, RM 3E70, National Institutes of
Health, NIAID, 5601 Fishers Lane, MSC 9834, Rockville, MD 20852-
9834, 240-669-2081, [email protected].
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Partnerships for Countermeasures
against Select Pathogens (R01).
Date: June 28-29, 2018.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Amir E. Zeituni, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities NIAID/NIH/DHHS, 5601 Fishers Lane, MSC-9834, Rockville,
MD 20852, 301-496-2550, [email protected].
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Partnerships for Countermeasures
against Select Pathogens (R01).
Date: July 10-11, 2018.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Amir E. Zeituni, Ph.D., Scientific Review
Officer Scientific Review Program Division of Extramural Activities
NIAID/NIH/DHHS, 5601 Fishers Lane, MSC-9834, Rockville, MD 20852,
301-496-2550, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: May 21, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-11215 Filed 5-24-18; 8:45 am]
BILLING CODE 4140-01-P
